Elisigen Inc.
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
Elisigen Inc. - overview
Established
2018
Location
Seoul, -, South Korea
Primary Industry
Biotechnology
About
Based in Seoul, South Korea, and founded in 2018, Elisigen Inc. operates as a biotechnology company that develops gene therapy to treat diseases through in vivo and ex vivo gene transfer methods. In January 2026, Elisigen Inc. raised KRW 5 billion in series C funding from NH Investment & Securities and DAYLI Partners, bringing the total amount raised in three series C rounds to KRW 42 billion.
Elisigen Inc. provides gene therapy products such as AAV vector-based gene therapy. The company also developed gene therapies for eye diseases such as age-related macular degeneration, chronic neuropathic pain, and cranial nerve diseases such as Alzheimer's disease. In addition, the firm focuses on developing NG101 for wet age-related macular degeneration and NG201 for neuropathic pain.
The company will use the January 2026 funding to support its clinical trials and international commercialization.
Current Investors
Partners Investment, SV Investment, Saehan Venture Capital
Primary Industry
Biotechnology
Sub Industries
Biopharmaceuticals, Molecular Science, Genetics & Gene Therapy, Healthcare
Website
www.elisigen.com/
Verticals
HealthTech
Company Stage
Series C
Total Amount Raised
Subscriber access only
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.